Amara Holdings Limited (SGX:A34): A Fundamentally Attractive Investment

In this article:

Attractive stocks have exceptional fundamentals. In the case of Amara Holdings Limited (SGX:A34), there’s is a well-regarded dividend-paying company with a an impressive track record of delivering benchmark-beating performance. Below, I’ve touched on some key aspects you should know on a high level. For those interested in digger a bit deeper into my commentary, read the full report on Amara Holdings here.

Proven track record average dividend payer

In the previous year, A34 has ramped up its bottom line by 34%, with its latest earnings level surpassing its average level over the last five years. Not only did A34 outperformed its past performance, its growth also exceeded the Hospitality industry expansion, which generated a -8.5% earnings growth. This is what investors like to see!

SGX:A34 Income Statement, March 5th 2019
SGX:A34 Income Statement, March 5th 2019

A34 is also a dividend company, with ample net income to cover its dividend payout, which has been consistently growing over the past decade, keeping income investors happy.

SGX:A34 Historical Dividend Yield, March 5th 2019
SGX:A34 Historical Dividend Yield, March 5th 2019

Next Steps:

For Amara Holdings, I’ve compiled three important aspects you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for A34’s future growth? Take a look at our free research report of analyst consensus for A34’s outlook.

  2. Financial Health: Are A34’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.

  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of A34? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Advertisement